IL1A and COVID-19: Indeed, several clinical trials are currently in progress to evaluate the benefits of using immunomodulators in COVID-19, and preliminary studies have been already published for anakinra, an IL-1 receptor antagonist that blocks the activity of IL-1α and IL-1β, canakinumab, a monoclonal antibody targeting IL-1β and tocilizumab, a monoclonal antibody that specifically targets IL-6 receptor (207–210).